CenturyLink (CTL): Merger Is Not Transformative, Keeping Sell Like Rating - Jefferies
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies analyst, Mike McCormack, reiterated his Underperform rating on shares of CenturyLink, Inc. (NYSE: CTL) and cut his price target to $20 from $24.
Despite the announced merger with LVLT, the analyst remains cautious on shares of CTL. The deal can prove to be highly accretive but the combination falls short in transforming the business as the enterprise market remains highly competitive and price sensitive. Synergies and taxes should prove beneficial to the dividend near-term, but do not provide a path for long term sustainability.
Shares of CenturyLink, Inc. closed at $26.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Lowered to $56 at Jefferies Amid Adult Tourette's Data
- Jefferies Downgrades Alcobra Ltd. (ADHD) to Hold
- Goldman Sachs Raises Eli Lilly (LLY) PT, Sees Catalysts In Coming Year, Maintains Conviction Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!